Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections

Highlights • Voriconazole Cmin of 1.5–4 mg/L will with appropriate clinical efficacy and safety. • CYP2C19 genetic status or Cmin / CN values will be help to dose-adjustment. • 200 mg twice-daily intravenously or orally for PMs are suitable. • 200 mg twice-daily intravenously or 300 mg twice-daily o...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of antimicrobial agents Vol. 44; no. 5; pp. 436 - 442
Main Authors:	Wang, Taotao, Zhu, Huifang, Sun, Jinyao, Cheng, Xiaoliang, Xie, Jiao, Dong, Haiyan, Chen, Limei, Wang, Xue, Xing, Jianfeng, Dong, Yalin
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-11-2014
Subjects:	Adolescent Adult Aged Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Chemical and Drug Induced Liver Injury CYP2C19 Cytochrome P-450 CYP2C19 - genetics Efficacy Female Fungemia - drug therapy Hepatotoxicity Humans Infectious Disease Male Meningitis, Fungal - drug therapy Middle Aged Plasma - chemistry Polymorphism, Genetic Safety Treatment Outcome Trough plasma concentrations Voriconazole Voriconazole - adverse effects Voriconazole - therapeutic use Young Adult Efficacy Trough plasma concentrations Safety CYP2C19 Hepatotoxicity Voriconazole
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Highlights • Voriconazole Cmin of 1.5–4 mg/L will with appropriate clinical efficacy and safety. • CYP2C19 genetic status or Cmin / CN values will be help to dose-adjustment. • 200 mg twice-daily intravenously or orally for PMs are suitable. • 200 mg twice-daily intravenously or 300 mg twice-daily orally for non-PMs are suitable.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0924-8579 1872-7913
DOI:	10.1016/j.ijantimicag.2014.07.013